<DOC>
	<DOCNO>NCT03081481</DOCNO>
	<brief_summary>The purpose study determine safe , effective , tolerable dose PRX302 treatment low intermediate risk prostate cancer .</brief_summary>
	<brief_title>Intraprostatic PRX302 Injection Treat Localised Prostate Cancer</brief_title>
	<detailed_description>A multi-centre , open label , phase IIb study , evaluate safety , tolerability efficacy target intraprostatic focal administration development . The study treat approximately 40 men meet eligibility criterion , give write consent . Safety tolerability assess post-treatment 26 week . Efficacy assess biopsy imaging ( mpMRI ) 24 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Life expectancy ≥ 10 year . Serum prostatespecific antigen ( PSA ) ≤ 15ng/mL . A histologically prove , clinically significant lesion visible mpMRI ( magnetic resonance imaging ) accessible PRX302 transperineal injection . Radiological stage T1T2 N0 Mx/M0 disease . Targeted prostate biopsy within 6 month prior dose , clinically significant lesion correlate mpMRI visible lesion . Previous radiation therapy pelvis . Androgen suppression antiandrogen therapy within 12 month prior dose , prostate cancer . Use 5alpha reductase inhibitor within 3 month prior dose . Evidence metastatic disease nodal disease outside prostate bone scan crosssectional imaging . Inability tolerate transrectal ultrasound ( TRUS ) . Known allergy latex gadolinium ( Gd ) . Prior rectal surgery prevent insertion TRUS probe . Any previous ablative procedure perform prostate , e.g. , electroporation , radiofrequency ablation , highintensity focus ultrasound ( HIFU ) , cryosurgery , photochemical , thermal microwave therapy treat cancer prostate . Unable pelvic MRI scanning ( severe claustrophobia , permanent cardiac pacemaker , metallic implant , etc. , likely contribute significant artifact image ) .</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Intraprostatic</keyword>
	<keyword>MRI lesion</keyword>
	<keyword>Prostate biopsy</keyword>
</DOC>